Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial - 25/08/20
, Renato Delascio Lopes, MD, PhD b, Leandro Barile Agati, PhD c, Roberto Sacilotto, MD, PhD a, Nelson Wolosker, MD, PhD d, j, Marcone Lima Sobreira, MD, PhD e, Bruno Leonardo de Freitas Soares, MD, PhD f, Edwaldo Edner Joviliano, MD, PhD g, Walkiria Hueb Bernardi, MD, PhD h, Valter Castelli Junior, MD, PhD h, Roberto Augusto Caffaro, MD, PhD h, Alexandre Fioranelli, MD, PhD h, Bonno Van Bellen, MD, PhD i, Ivan Benaduce Casella, MD, PhD j, Ronald José Ribeiro Fidelis, MD, PhD k, Ronald Luiz Gomes Flumignan, MD, PhD l, Anthony James Comerota, MD, FACS m, Eduardo Ramacciotti, MD, PhD n, hAbstract |
Background |
New antithrombotic strategies that reduce primary thrombosis and restenosis might improve vascular outcomes in patients with peripheral artery disease (PAD) undergoing arterial angioplasty. The study objective is to evaluate the potential benefit of apixaban plus aspirin compared with standard of care dual antiplatelet therapy (DAPT) in reducing thrombotic restenosis and artery re-occlusion in patients undergoing endovascular infrapopliteal revascularization.
Study design |
This multicenter, parallel-group, prospective, randomized, open-label, blinded-endpoint adjudication, proof-of-concept, exploratory trial aims to randomize 200 patients 72 hours after successful infrapopliteal angioplasty for critical limb ischemia (CLI). Patients will be randomly assigned in a 1:1 ratio to receive oral apixaban (2.5 mg twice daily) plus aspirin (100 mg once daily) for 12 months or clopidogrel (75 mg daily) for at least 3 months on a background of aspirin (100 mg once daily) for 12 months. The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events – MACE (myocardial infarction, stroke or cardiovascular death) at 12 months. The primary safety endpoint is the composite of major bleeding or clinically relevant non-major bleeding at 12 months.
Summary |
This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared with DAPT (clopidogrel plus aspirin) in patients with CLI undergoing endovascular infrapopliteal revascularization and might prove the concept of an alternative antithrombotic regimen for these patients to be tested in a future large randomized clinical trial.
Le texte complet de cet article est disponible en PDF.Plan
| Matthew Aaron Cavender, MD, MPH served as guest editor for this article. |
Vol 227
P. 100-106 - septembre 2020 Retour au numéro
Article précédent
- Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve
- Oliver K. Jawitz, Tracy Y. Wang, Renato D. Lopes, Alma Chavez, Brittanny Boyer, Hwasoon Kim, Kevin J. Anstrom, Richard C. Becker, Eugene Blackstone, Marc Ruel, Vinod H. Thourani, John D. Puskas, Marc W. Gerdisch, Douglas Johnston, Scott Capps, John H. Alexander, Lars G. Svensson
- Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial
- Wijnand K. den Dekker, Nicolas M. Van Mieghem, Johan Bennett, Manel Sabate, Giovanni Esposito, Rutger J. van Bommel, Joost Daemen, Matthias Vrolix, Paul A. Cummins, Mattie J. Lenzen, Eric Boersma, Felix Zijlstra, Roberto Diletti, on Behalf of the BioVasc Trial Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?